In January 2016, we entered into a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck’s KEYTRUDA®. We initiated this study in the second half of 2016 with the objective of demonstrating that the combination of drugs has the potential to expand the benefit of immunotherapy to cancer types currently resistant to immuno-oncology treatments.
In September 2016, we entered into a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech’s atezolizumab in several Phase 1b studies for multiple solid tumor indications and AML. Again, the objective is to expand the benefit of immunotherapy to cancer types currently resistant to immuno-oncology treatments.
In December 2014, we entered into a strategic, multi-year co-development agreement with Novartis for co-development of selected programs, with an emphasis on Israeli-sourced programs. Novartis chose BioLineRx as its leading partner for identification and early development of novel Israeli-sourced drug candidates. The companies intend to co-develop a number of pre-clinical and early clinical therapeutic projects through clinical proof-of-concept.